Match tier Likely match
Presence Current · Arkansas
Last published 2026
Sources OpenAlex · ORCID
Refreshed 2026-10-01

Daniel Armstrong

This is a likely match — the affiliation was inferred from OpenAlex, ORCID, and web sources but has not been fully confirmed. Treat with appropriate caution.

Role not yet determined Is this you? Add your title

1 pubs

  • Antineoplastic Agents
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms
  • Quinazolines
  • Protein Kinase Inhibitors
  • Proto-Oncogene Proteins c-ret
  • Drug Discovery
  • Aurora Kinase B
  • Dose-Response Relationship, Drug
  • Drug Screening Assays, Antitumor
  • Humans
  • Structure-Activity Relationship
  • Molecular Structure
  • Cell Line, Tumor
  • Cell Proliferation

Biography and Research Information

OverviewAI-generated summary

Daniel Armstrong's research focuses on the discovery of quinazoline-based dual inhibitors targeting RET and Aurora B kinases. This work is aimed at developing potential treatments for non-small cell lung cancer. His recent publication in 2026 highlights his active engagement in this area of study.

Metrics

  • Publications: 1

Selected Publications

  • Discovery of quinazoline-based dual RET/Aurora B inhibitors for non-small cell lung cancer (2026)
    Bioorganic Chemistry DOI OpenAlex

View all publications on OpenAlex →

Collaboration Network

10 Collaborators 2 Institutions 2 Countries

Top Collaborators

View profile →
View profile →
View profile →
View profile →
View profile →
View profile →
View profile →
View profile →

Similar Researchers

Based on overlapping research topics